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Abstract
Background: Atypical antipsychotic medications are widely prescribed for the adjunctive treatment of depression, yet their
total risk–benefit profile is not well understood. We thus conducted a systematic review of the efficacy and safety profiles of
atypical antipsychotic medications used for the adjunctive treatment of depression.
Methods and Findings: We included randomized trials comparing adjunctive antipsychotic medication to placebo for treatment-
resistant depression in adults. Our literature search (conducted in December 2011 and updated on December 14, 2012) identified 14
short-term trials of aripiprazole, olanzapine/fluoxetine combination (OFC), quetiapine, and risperidone. When possible, we
supplemented published literature with data from manufacturers’ clinical trial registries and US Food and Drug Administration New
Drug Applications. Study duration ranged from 4 to 12 wk. All four drugs had statistically significant effects on remission, as follows:
aripiprazole (odds ratio [OR], 2.01; 95% CI, 1.48–2.73), OFC (OR, 1.42; 95% CI, 1.01–2.0), quetiapine (OR, 1.79; 95% CI, 1.33–2.42), and
risperidone (OR, 2.37; 95% CI, 1.31–4.30). The number needed to treat (NNT) was 19 for OFC and nine for each other drug. All
drugs with the exception of OFC also had statistically significant effects on response rates, as follows: aripiprazole (OR, 2.07; 95% CI,
1.58–2.72; NNT, 7), OFC (OR, 1.30, 95% CI, 0.87–1.93), quetiapine (OR, 1.53, 95% CI, 1.17–2.0; NNT, 10), and risperidone (OR, 1.83, 95%
CI, 1.16–2.88; NNT, 8). All four drugs showed statistically significant effects on clinician-rated depression severity measures (Hedges’ g
ranged from 0.26 to 0.48; mean difference of 2.69 points on the Montgomery–Asberg Depression Rating Scale across drugs). On
measures of functioning and quality of life, these medications produced either no benefit or a very small benefit, except for
risperidone, which had a small-to-moderate effect on quality of life (g=0.49). Treatment was linked to several adverse events,
including akathisia (aripiprazole), sedation (quetiapine, OFC, and aripiprazole), abnormal metabolic laboratory results (quetiapine
and OFC), and weight gain (all four drugs, especially OFC). Shortcomings in study design and data reporting, as well as use of post
hoc analyses, may have inflated the apparent benefits of treatment and reduced the apparent incidence of adverse events.
Conclusions: Atypical antipsychotic medications for the adjunctive treatment of depression are efficacious in reducing
observer-rated depressive symptoms, but clinicians should interpret these findings cautiously in light of (1) the small-to-
moderate-sized benefits, (2) the lack of benefit with regards to quality of life or functional impairment, and (3) the abundant
evidence of potential treatment-related harm.
Please see later in the article for the Editors’ Summary.
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Atypical antipsychotic medications are widely used in the
treatment of major depressive disorder. In the United States in
2007 and 2008, there were an estimated 3.9 million treatment visits
per year in which an antipsychotic medication was prescribed for
depression, and nearly all of these (96%) involved prescription of an
atypical antipsychotic medication [1]. Although aggregate statistics
mask the specific indications for use (i.e., monotherapy versus
adjunctive therapy), this represents a substantial increase in
antipsychotic treatment of depression over time, as there were just
over 2 million such visits annually during 1995 and 1996, of which
405,000 involved prescriptions for atypical antipsychotic medica-
tions. These data are also consistent with market reports from
industry [2]. Three atypical antipsychotic medications have
approval from the US Food and Drug Administration (FDA) as
adjunctive therapies in depression for adults, while none are
approved for monotherapy. These approvals (and subsequent
marketing efforts), along with the volume of prescriptions, suggest
that a large number of prescriptions for atypical antipsychotic
medications written for the treatment of depression are being used
for adjunctive therapy [3–5].
The efficacy of adjunctive atypical antipsychotic therapy in
reducing depression symptom severity in major depressive
disorder is summarized in two previous systematic reviews, but
neither comprehensively summarized data on both efficacy and
safety [6,7]. Both reviews analyzed efficacy only in terms of
dichotomous response and remission outcomes derived from
clinician-rated depression measures and did not assess changes in
terms of symptom severity on the underlying continuous rating
scales. Safety was only assessed by examining dropout rates due to
adverse events; the authors of these meta-analyses [6,7] and of a
relevant narrative review noted that a comprehensive summary of
safety data is lacking [8]. A Cochrane review provided a more
thorough assessment of both efficacy and safety outcomes but did
not include data on important patient-centered efficacy outcomes
such as patient-rated depression, functional impairment, or quality
of life [9]. The Cochrane review assessed the frequency of several
relevant adverse events, but some critical adverse events of
interest, such as elevated cholesterol or triglyceride levels, were not
included. Further, and most importantly, effect size estimates
presented in these reviews may have been inflated because the
authors did not summarize unpublished data, such as those from
FDA New Drug Applications (NDAs) or manufacturers’ clinical
trial registries [10–13]. Given the importance of functional status,
quality of life, and drug-related side effects to the overall
assessment of well-being and recovery from depressive mood
episodes [14–16], we conducted this meta-analysis to provide a
comprehensive estimate of the efficacy and safety profiles of
atypical antipsychotic medications for the adjunctive treatment of
major depressive disorder.
Methods
Ethical Review
Because this was a study-level systematic review and meta-
analysis of trials, and did not involve collection and analysis of any
individual-level data, ethical approval was not sought for this
study.
Search Strategy
This systematic review was reported using PRISMA guidelines;
the PRISMA checklist is provided as Text S1. To identify both
published and unpublished studies for review, we searched
Medline, PsycINFO, ClinicalTrials.gov, and the Cochrane Cen-
tral Register of Controlled Trials using the terms depression AND
(aripiprazole OR asenapine OR clozapine OR iloperidone OR lurasidone
OR olanzapine OR paliperidone OR quetiapine OR risperidone OR
ziprasidone). Medline search results were restricted to the following
article types: clinical trial, controlled clinical trial, or randomized
controlled trial. Our literature search was conducted in December
2011 and updated on December 14, 2012. In addition, we
searched the American Psychiatric Association Annual Meeting
New Research Abstracts for 2001–2010 using each of the generic
drug names as a search term, then winnowed the results down to
abstracts that appeared to possibly meet the inclusion criteria. We
also examined all references in a previously published meta-
analysis [6] as well as those contained in each published study
obtained through our literature search.
To obtain additional unpublished data, we searched the drug
manufacturers’ online clinical trial registries as well as FDA NDAs
for the atypical antipsychotic medications that have received an
indication for the adjunctive treatment of major depressive
disorder (aripiprazole, olanzapine-fluoxetine combination
[OFC], and quetiapine). For published studies, we supplemented
published data with data available in NDAs or clinical trial registry
reports whenever such data were available.
Study Selection
Trials were included if they were acute-phase (i.e., not for
relapse prevention or maintenance treatment [17,18]), placebo-
controlled trials in which participants treated with antidepressant
medications were randomly assigned to additionally receive an
atypical antipsychotic medication or placebo. In order to meet our
definition of treatment-resistant depression, participants must have
been diagnosed with current major depressive disorder and must
have been determined to have had an inadequate response to at
least one course of antidepressant medication treatment prior to
enrollment in the study. Furthermore, data for at least one
outcome measure must have been reported in a manner that
allowed calculation of an effect size. No language exclusions were
applied.
Data Extraction
Four study authors (G. I. S., A. P., M. I. B., and E. L.) coded
study descriptor data. To establish consistency, all coders first
coded the articles reporting outcomes from the aripiprazole
studies. Then two study authors (G. I. S. and A. P.) jointly coded
the OFC and risperidone articles, and two study authors (M. I. B.
and E. L.) jointly coded the quetiapine articles. Disagreements
were resolved by consensus. Coders were not blind to the results of
the coded studies.
Several descriptor variables were coded for each study. (1)
Flexible dosing versus fixed dosing regimen. (2) Dosage range. (3)
Mean dosing achieved at end point. (4) Number of participants in
each group of trial. (5) Duration of acute-phase treatment (weeks).
(6) Number of prior failed trials of antidepressant medications,
where the number of failed trials prior to study enrollment
(historical) and the number of failed trials during the study
(prospective) prior to initiation of the study drug for adjunctive
treatment were recorded separately. (7) Procedures employed to
evaluate for major depressive disorder (structured interview or
otherwise). (8) Use of a structured instrument versus open-ended
questioning to elicit adverse events [19,20] (with the latter assumed
if no details were reported). (9) Adverse events scale(s) used to
systematically assess for any particular adverse event(s), if any. (10)
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adverse events reporting in the trial (e.g., if only those adverse
events occurring in at least 5% of participants were reported in the
associated journal article, the adverse events reporting threshold
was coded as 5%). (11) Extent to which the random-sequence
generation procedures were adequate versus inadequate or
unclear [21]. Adequate sequence generation procedures included
use of a computer program, random number table, coin tossing,
randomly drawing envelopes, throwing dice, or similar methods.
Merely describing the trial as randomized was considered an
unclear method of sequence generation. (12) Whether or not the
study eliminated placebo responders prior to randomization. (13)
Whether or not persons who had a prior nonresponse to the study
drug were excluded. (14) Whether or not the placebo was
described as identical to the study drug in terms of at least two of
the following three criteria: taste, appearance, and smell [22]. (15)
Use of blinded raters, coded as affirmative if the following two
conditions were met: (a) it was explicitly stated that blinded raters
were used, and (b) it was explicitly stated that different personnel
were used to rate efficacy measures and adverse events [23–25].
(16) Funding sponsor.
Efficacy and safety outcome data were independently extracted
by two authors (G. I. S. and A. P.) and then checked for
agreement. Disagreements were resolved by checking the original
data source.
Outcome Measures
Remission was defined variably across studies. We recorded the
most stringent definition of remission utilized in each trial while
also recognizing that the Montgomery–Asberg Depression Rating
Scale (MADRS) [23] was the most commonly used outcome
measure in the included trials. One end-point remission measure
was selected from each trial according to the following order of
priority: MADRS #8, then Hamilton Depression Rating Scale
(HAM-D) #7 [24], then MADRS #10. Some trials of OFC
defined remission as MADRS #8 at two consecutive visits during
the study even if these two consecutive visits did not necessarily
occur at study end point [25–27]. The clinical trial registry reports
of these trials also provided the number of participants who met
remission criteria at an interim time point but then relapsed. For
these studies, we calculated the number of participants in
remission as the number of participants who achieved interim
remission minus the number of patients who subsequently
relapsed.
Response was defined across studies as a 50% improvement
from baseline to end point on either the MADRS or HAM-D [28].
When studies provided response rates for both measures, we used
the MADRS as the response measure, as it was the most
commonly reported measure of response.
We recorded data from any continuous measure of depression,
quality of life, or functioning but opted not to analyze single rating
scale items from larger scales (e.g., individual MADRS items)
separately because they were infrequently reported. When data
were reported on both the MADRS and HAM-D, we included
data from the MADRS, as it was the most commonly used
measure of depressive symptoms. The only continuous self-report
measure of depression used in these trials was the Inventory of
Depressive Symptomatology Self Report [29]. Continuous mea-
sures of quality of life included the Quality of Life Enjoyment and
Satisfaction Questionnaire (Q-LES-Q) [30] and the Short Form 36
Health Survey (SF-36) [31]. The only continuous measure of
functional impairment employed in these trials was the Sheehan
Disability Scale (SDS) [32]. As measures of quality of life and
functional impairment varied across studies, we pooled such
measures together to create an omnibus effect size for each drug,
and across all drugs.
We aggregated conceptually similar adverse events into the
following categories. (1) Sedation-related: asthenia, fatigue, leth-
argy, sedation, somnolence, or feeling tired. (2) Akathisia-related
(either self-reported or observer-rated): akathisia or restlessness. (3)
Extrapyramidal symptoms (EPS), other than akathisia-related
(either self-reported or observer-rated): dyskinesia, dystonia,
extrapyramidal disorder, EPS, muscle spasms, muscle twitching,
parkinsonism, or tremor. (4) Abnormal metabolic laboratory
results: elevated fasting or nonfasting total cholesterol, low-density
lipoprotein (LDL) cholesterol, or triglycerides; low high-density
lipoprotein (HDL) cholesterol; or elevated fasting or nonfasting
glucose, glycated hemoglobin; or hyperglycemia. (5) Elevated
prolactin. (6) Edema or peripheral edema. (7) Significant weight
gain, defined across various trials as weight gain of $7%, $10%,
or .10% from baseline to end point.
We also coded events that were reported in the categories of
pain, psychiatric events, nausea, and infection. However, because
no sign of elevated risk was gleaned from these data, these analyses
are not reported (data available from authors on request).
Statistical Analysis
The quality of data reporting varied across studies. For
continuous outcomes, effect sizes were computed from means
and standard deviations when possible. When these were not
provided, effect sizes were computed based on means and p-values,
or p-values only. In some studies, three or more treatment groups
were compared, thereby creating a structural dependency that
could affect our estimates. For example, two fixed doses (A and B)
of an adjunctive atypical antipsychotic medication might be
compared to one group that received adjunctive placebo (C), in
which case the estimated efficacy of A and B would be defined
relative to the same comparison group. To maintain indepen-
dence, we pooled these comparisons and utilized their average
(e.g., the average of A versus C and B versus C).
Each effect size was weighted by its inverse variance in order to
provide a pooled effect size estimate that most accurately
approached the true population effect size [33]. We calculated
odds ratios (ORs) for categorical measures and used Cohen’s d for
continuous measures. We converted continuous effect sizes to
Hedges’g, which corrects for a small bias in Cohen’s d [33]. We
reported both efficacy and safety data for each drug individually
and across drugs. An OR presents a relative measure of treatment
effect; to also provide a measure of absolute benefit/harm, we
calculated the number needed to treat (NNT) for treatment
benefits and the number needed to harm (NNH) for adverse events
[34]. The NNT represents the number of participants who would
need to be treated with an adjunctive antipsychotic to gain one
additional beneficial response over what would have been
obtained had all patients received adjunctive placebo. NNH
represents the number of patients who would require treatment to
generate one additional adverse event relative to placebo. NNT/
NNH values were calculated based on the pooled OR rather than
from the risk difference in each study, as the risk difference is
associated with more between-study heterogeneity than the OR
[35]. Conversions from OR to NNT were performed in Visual Rx
software [36]. The baseline risk (required for calculating NNT)
was estimated by using the pooled rate of events occurring among
placebo-treated patients weighted by each study’s total sample
size. The baseline risk was calculated separately for each drug, so
that placebo participants in one drug’s trials were not used to
calculate baseline risk for a different drug. As in any meta-analysis,
our estimates of NNT and NNH generalize only to situations in
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PLOS Medicine | www.plosmedicine.org 3 March 2013 | Volume 10 | Issue 3 | e1001403which patients receive a similar dosage for a similar treatment
duration; further, estimated NNH and NNT apply only when
generalizing to patients similar to those in the included trials.
Because of various study inclusion and exclusion criteria, patients
in the placebo groups in our meta-analysis may not be
representative of patients seen in some clinical practice settings.
We performed homogeneity analyses using the Q statistic.
Because the Q test of homogeneity often lacks power to detect
heterogeneity when the number of trials in a meta-analysis is small,
we also calculated the I
2 statistic [37]. To pool estimates across
studies while incorporating potential heterogeneity, we employed a
random effects model in all analyses [38]. Confidence intervals for
I
2 were calculated using Method III as described in Higgins and
Thompson [39] using a spreadsheet. When performing such
calculations in pooled analyses based on only two comparisons
when Q#k, we added the number 1 to both Q and k in order to
avoid the mathematical problem of dividing by zero; this generally
resulted in a slight shrinking of the confidence intervals under
these conditions. Unless specified otherwise above, all analyses
were performed using Comprehensive Meta-Analysis software
[40]. We lacked adequate statistical power to perform subgroup
analyses.
We examined the potential existence of publication bias by
performing trim and fill analysis for pooled continuous depression
outcomes. Trim and fill procedures examine potential asymmetry
of effect sizes. Based on the assumption that effects are distributed
symmetrically, trim and fill analysis imputes the number and likely
effect size of missing studies, then recalculates the pooled analysis
with imputed data from missing studies [41].
Results
Study Characteristics
The evidence search flow is described in Figure 1. We obtained
one controlled trial of aripiprazole that used low doses (2 or 5 mg);
we did not include this trial because the starting dose of 2 mg was
administered for 30 d prior to participants switching to the dose of
5 mg that falls within the recommended 5–10 mg range set by the
FDA [42]. Characteristics of the 14 included studies are provided
in Table 1. The definition of treatment-resistant depression
differed somewhat across trials. The process by which diagnoses
were made was described clearly in six trials, and the number of
prior failed trials varied across studies. Only three studies clearly
described their random-sequence generation procedures, and only
one trial clearly described using clinical raters who were blind to
both treatment assignment and participants’ reports of adverse
events. While most trials used rating scales to assess for EPS and
akathisia, and a minority of trials used a measure of sexual
functioning, no trial reported using a structured instrument for
eliciting a broad range of adverse events. All studies were funded
by the study drug manufacturer except for one trial that was
funded jointly by the study drug manufacturer and the US
National Institute of Mental Health [27].
Efficacy
In terms of remission, adjunctive treatment with each antipsy-
chotic was associated with a statistically significant benefit, with
ORs ranging from 1.42 to 2.37 (Table 2). ORs for response were
also statistically significant for aripiprazole, quetiapine, and
risperidone—but not for OFC (Table 2). The NNT for remission
was nine for aripiprazole, quetiapine, and risperidone but was a
substantially higher 19 for OFC (Table 2). NNTs for response
were seven (aripiprazole), eight (risperidone), and ten (quetiapine).
Pooled ORs are displayed visually in Figures 2 and 3 [43]. Among
participants who achieved remission during treatment, partici-
pants assigned to OFC were less likely to remain in remission than
participants assigned to placebo. Only two of 56 placebo
participants relapsed, compared to 18 relapses among 99
participants on OFC (OR, 0.27; 95% CI, 0.08–0.90).
Pooled effect sizes for continuous outcomes are provided in
Table 3. Adjunctive aripiprazole, quetiapine, OFC, and risperi-
done were all more efficacious than adjunctive placebo based on
clinician-rated measures of depression severity (MADRS/HAM-
D). Effect sizes were as follows: aripiprazole: g=0.35 (95% CI,
0.23–0.48); OFC: g=0.26 (95% CI, 0.04–0.45); quetiapine:
g=0.40 (95% CI, 0.26–0.53); and risperidone: g=0.48 (95% CI,
0.22–0.73). The effects of risperidone may have been exaggerated
by the reliance on post hoc analysis rather than a priori analysis in
the largest study of the drug, as the effect of the drug was greater at
6w k( g=0.46) than at the prespecified primary end point of 4 wk
(g=0.32) [44]. According to convention, these effect sizes would be
considered ‘‘small’’ or ‘‘small to moderate’’ in magnitude [45].
Effect sizes on depression severity measures did not differ
significantly between drugs (QB=1.93, p=0.59), though there
was limited power to detect such differences. The pooled
difference in mean change on the MADRS in the 11 trials that
reported such data was 2.69. In these 11 trials, the mean effect size
was g=0.31, which differed only slightly from the overall mean
effect size when including both the HAM-D and MADRS; thus,
the 11 trials reporting MADRS mean change data seem
representative of the entire sample of included trials. Only the
trials of adjunctive aripiprazole reported self-reported depression
symptom severity, yielding a very small effect size of g=0.15. The
effects observed on the Clinical Global Impressions–Severity Scale
were either small or small-to-moderate, with the exception of
risperidone, for which a moderate effect was generated.
With regards to quality of life and functioning, adjunctive
quetiapine, aripiprazole, and OFC produced effect sizes that were
either not statistically significant or small and clinically negligible
in magnitude. Adjunctive risperidone was more efficacious than
adjunctive placebo on quality of life/functioning, with a small-to-
moderate effect size. The pooled effect across quality of life/
functioning measures varied significantly across treatments
(QB=6.88, p=0.003), with risperidone (g=0.49) yielding a higher
effect than the other three drugs combined (g=0.11), which did
not differ significantly from each other (QB=4.02, p=0.13).
However, the effect of aripiprazole on quality of life/functioning
was small (g=0.22) and statistically significant (p=0.001), whereas
the effects of OFC (g=0.04, p=0.74), and quetiapine (g=0.05,
p=0.53) were both not statistically significant and of quite small
magnitude. The effect of aripiprazole on quality of life/functioning
should be interpreted with caution, as the effect for the drug on the
SDS was very small and no longer statistically significant when
patients who violated study protocol were excluded from analysis
(g=0.12, p=0.08). Similarly, the effect of risperidone on quality of
life/functioning should be interpreted tentatively since it is largely
driven by post hoc analyses.
Adverse Events
Atypical antipsychotic medications differed substantially in their
reported adverse event profiles. Table 2 reports adverse events that
showed increased risk (p#0.10). A more detailed listing of adverse
events and pooled ORs for each event category are provided in
Table 4.
Adjunctive aripiprazole was frequently associated with akathisia
(NNH, 4; 95% CI, 3–6) and also linked to a statistically significant
elevation in the occurrence of sedation (NNH, 14; 95% CI, 8–33)
and significant weight gain of $7% during trials (NNH, 29; 95%
Atypical Antipsychotic Augmentation for MDD
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weight gain of .10% or $10% (NNH, 9; 95% CI, 5–20), sedation
(NNH, 5; 95% CI, 3–12), abnormal metabolic laboratory results
(NNH, 10; 95% CI, 5–29), and elevated prolactin (NNH, 6; 95%
CI, 4–11). Adjunctive quetiapine had a very high rate of reported
sedation (NNH, 3; 95% CI, 2–3) and was also linked to abnormal
metabolic laboratory results (NNH, 6; 95% CI, 4–9) and
significant weight gain of $7% (NNH 37; 95% CI, 12–594).
Adjunctive risperidone was not associated with an increased rate of
any spontaneously reported adverse events.
All four drugs resulted in statistically significant weight gain
(Table 3): mean weight gain in trials of adjunctive aripiprazole,
quetiapine, and risperidone was approximately 1 kg, while the
average weight gain resulting from adjunctive OFC was 4.20 kg
(95% CI, 3.79–4.61). OFC was associated with more weight gain
than the other drugs (QB=58.46, p,0.001), which did not differ
significantly from each other (QB=0.66, p=0.72).
The thresholds for adverse event reporting in the included
publications are shown in Table 1. Adverse events were typically
listed in a tableand werereported onlyif a certain proportion of study
participants reported that event. For example, if only those adverse
events reported by 5% or more of participants in either group were
reported in the published journal article, we describe it in Table 1 as
‘‘$5% in any group.’’ In general, little to no additional information
was provided in the study publications regarding adverse events
beyond that which was presented in such tables. Meta-analysis of
effects on sexual functioning rating scales was not performed because
of the often unclear reporting of these measures (see Table 3).
Publication Bias
The trim and fill procedure suggested the existence of three
unpublished trials, bringing the overall effect on depression
measures to 0.32. A funnel plot showing the results of this analysis
can be seen in Figure 4.
Figure 1. Flowchart of published studies examined for inclusion in meta-analysis. MDD, major depressive disorder; RCT, randomized
controlled trial.
doi:10.1371/journal.pmed.1001403.g001
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In this meta-analysis of 14 randomized trials of atypical
antipsychotic medications used for the adjunctive treatment of
major depressive disorder, we found that all included atypical
antipsychotics were more efficacious than adjunctive placebo in
terms of their effects on depressive symptom severity and
remission. However, the effect sizes were small or small-to-
moderate in magnitude, and OFC did not generate a statistically
significant benefit on treatment response. All of the studied drugs
except risperidone demonstrated substantial risk of several adverse
events. Our findings have clinically important implications for
comprehensively understanding the risk–benefit profiles of these
adjunctive treatments for major depressive disorder.
The overall effect size on depression severity was g=0.34, an
effect conventionally deemed as small. In a meta-analysis of
antidepressants versus placebo, Kirsch et al. found an effect size of
0.32, which they interpreted as not clinically relevant [46]. This
was in line with the recommendations of the National Institute for
Health and Clinical Excellence in the United Kingdom, which
deemed effect sizes of g,0.5 as clinically insignificant, though no
evidence was cited for this cutoff [47]. However, Turner et al.’s
meta-analysis of antidepressants versus placebo found an effect size
of 0.31 [11], which was interpreted as ‘‘measurable and
significant’’ [48]. These differing interpretations are understand-
able given that Cohen noted that his original categorization of
effect sizes (0.2=small, 0.5=medium, and 0.8=large) was
arbitrary [45]. We interpret the effect of adjunctive antipsychotic
treatment on depression measures as of questionable clinical
relevance. In addition, sole reliance on depression rating scales to
determine treatment benefit is likely inadequate in understanding
overall treatment efficacy.
The pooled difference in mean change across 11 trials was 2.69
points on the MADRS. The MADRS consists of ten items, each
rated on a 0–6 scale, assessing sadness, inner tension, reduced
sleep, loss of appetite, concentration, difficulty with starting daily
activities, inability to feel, pessimism, and suicidal thoughts. A
small difference favoring an atypical antipsychotic over placebo on
the MADRS may thus reflect small differences across several
dimensions, or perhaps a sizable difference on one or two
dimensions combined with nil differences on other items. For
instance, a pooled analysis of the two large quetiapine trials
Table 2. Summary of dichotomous efficacy and safety measures.
Comparison Outcome k OR (95% CI)
a QI
2 (95% CI) p(Q) NNT/NNH (95% CI)
All combined Remission 13 1.77 (1.49–2.09) 9.20 0% (0%–43.38%) 0.69 10 (8–15)
Response 13 1.61 (1.33–1.95) 19.29 37.78% (0%–67.76%) 0.08 9 (7–16)
Aripiprazole Remission 3 2.01 (1.48–2.73) 0.34 0% (0%–38.81%) 0.84 9 (6–18)
Response 3 2.07 (1.58–2.72) 1.60 0% (0%–87.0%) 0.45 7 (5–12)
Akathisia 3 7.47 (5.07–11.0) 1.63 0% (0%–87.24%) 0.44 4 (3–6)
Sedation 3 2.56 (1.63–4.03) 0.68 0% (0%–69.41%) 0.71 14 (8–33)
Weight gain $7% 3 5.91 (2.14–16.29) 0.57 0% (0%–63.50%) 0.75 29 (10–119)
OFC Remission 5 1.42 (1.01–2.0) 4.72 15.19% (0%–82.38%) 0.32 19 (9–713)
Response 5 1.30 (0.87–1.93) 8.13 50.78% (0%–81.95%) 0.09 17 (NNH 34; NNT 7)
b
Weight gain $10% 4 16.28 (7.02–37.76) 0.88 0% (0%–47.80%) 0.83 9 (5–20)
Elevated metabolic
lab results
4 4.46 (2.07–9.58) 4.50 33.38% (0%–76.44%) 0.21 10 (5–29)
Sedation
c 3 2.87 (1.64–5.03) 7.83 74.45% (0%–92.32%) 0.02 5 (3–12)
Edema
d 3 13.19 (5.46–31.89) 0.24 0% (0%–13.32%) 0.89 7 (4–16)
Elevated prolactin 4 4.30 (2.36–7.83) 4.91 38.84% (0%–79.16%) 0.18 6 (4–11)
Akathisia 4 1.48 (0.96–2.30) 3.17 5.36% (0%–85.51%) 0.37 28 (NNH 11; NNT 321)
b
Quetiapine Remission 3 1.79 (1.33–2.42) 0.42 0% (0%–50.47%) 0.81 9 (6–19)
Response 3 1.53 (1.17–2.0) 0.79 0% (0%–73.67%) 0.67 10 (6–26)
Sedation 3 8.36 (5.83–11.98) 1.73 0% (0%–87.98%) 0.42 3 (2–3)
Elevated metabolic
lab results
2 2.45 (1.80–3.34) 0.40 0% (0%–85.14%) 0.53 6 (4–9)
Weight gain $7% 3 2.86 (1.11–7.37) 0.97 0% (0%–78.55%) 0.62 37 (12–594)
Risperidone Remission 2 2.37 (1.31–4.30) 0.01 0% (0%–79.40%) 0.92 9 (5–35)
Response 2 1.83 (1.16–2.88) 0.54 0% (0%–86.49%) 0.46 8 (5–33)
Measures of response and remission are reported for each treatment. Adverse events measures are reported for events that reached a statistical threshold of p,0.10 in
terms of OR. For further description of the data underlying the adverse events effect sizes, see Table 4.
aTrials with no events in either study arm are not included in summary OR calculations.
bThe 95% confidence interval included the possibility of both treatment-related benefit and treatment-related harm.
cBecause the total number of events in the OFC group was higher than the sample size of the group in Shelton et al [27], an effect size could not be calculated, and it
was thus not factored into the overall effect size estimate for sedation. Given the very small sample of the study, this makes virtually no difference in the overall effect
size estimate.
dThe four trials in which edema was reported for OFC participants had an average rate of 18.32%. Edema was not listed as an adverse event in Shelton et al [26] for any
participants in either the OFC or placebo group. As these data did not fit with the other OFC trials, we excluded this study from the calculation of the risk for placebo
participants.
doi:10.1371/journal.pmed.1001403.t002
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and quetiapine at 300 mg/d were superior to placebo by 2.50 and
2.85 points on the MADRS at study end point, respectively [49].
The treatment advantage in terms of the items ‘‘apparent sadness’’
and ‘‘reported sadness’’ appears to be about a third of that for the
‘‘reduced sleep’’ item (Figure 3b of [49]), suggesting that
quetiapine’s sedative effect on sleep may account for a substantial
degree of the observed improvement in depression scores. Thus,
improvement in overall depression rating scales should be
interpreted cautiously.
Response and remission rates are often used to convey the
magnitude of treatment benefit; however, these categorical
measures are created arbitrarily from underlying continuous
rating scale data [50]. In some circumstances these categorical
measures may inflate treatment differences relative to mean
change on the continuous scale [51]. While response and
remission rates are potentially useful outcome measures, they
should be considered only in the context of a wider set of outcome
data.
With the exception of risperidone, nearly all of the included
trials estimated small or minimal benefits with regards to quality of
life and functional impairment. Quetiapine and OFC generated
no benefit on such measures, whereas the benefits of aripiprazole
were statistically significant yet quite modest. Although risperidone
appeared to possess the strongest risk–benefit profile in our
analyses, our findings about risperidone were based on the smallest
sample size of any of the included drugs. We also have concerns
about data reported in the largest risperidone trial. The published
version of the study emphasizes outcomes at the end of the 6-wk
trial [44]. However, in its discussion section and the trial’s
associated ClinicalTrials.gov registry entry [52], it is mentioned
that the primary study end point was actually 4 wk; this is
mentioned neither in the paper’s methods section nor in the
abstract. The effect size on the HAM-D is 30% smaller at the 4-wk
end point relative to the 6-wk end point. Effects on the Q-LES-Q
and SDS were reported only at week 6, but it seems likely that
these effects would be smaller at the primary study end point.
Given that this study included 69% of the total participants in
risperidone trials, our pooled estimate of risperidone efficacy is
therefore driven by the inclusion of post hoc analyses. Further, a
previously published relapse prevention study (not included in our
meta-analysis due to its study design) found no benefit for
risperidone over placebo, suggesting that risperidone-related gains
may be transient [53,54].
Taken together, our findings raise significant concerns regard-
ing the impact of these medications in improving overall well-being.
Although improvements in quality of life or functional status
commonly co-occur with improvements in depression symptom
severity, this cannot automatically be assumed. One comprehen-
sive literature review estimated only a moderate degree of
correlation between these constructs [55]. It has been argued that
changes on quality of life measures may lag changes on depressive
symptom measures and that short-term trials may not be an
appropriate setting in which to estimate changes on quality of life
measures [15]. Contrary to this argument, however, four of five
recently published short-term antidepressant medication trials
Figure 2. Remission rates by drug and overall.
doi:10.1371/journal.pmed.1001403.g002
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measures of (1) quality of life or functional impairment (e.g., as
measured by the Q-LES-Q and SDS) and (2) depression symptom
severity (e.g., as measured by the HAM-D and MADRS) [56–60].
Our findings highlight the fact that reporting data only on
symptom response and resolution may provide an incomplete and
perhaps overly optimistic summary of a medication’s overall effects
on well-being [15,16,61]. More robust assessments of quality of life
and functional impairment should be incorporated into the design
of clinical trials of any putative antidepressant.
Without longer-term data on not only depression symptom
severity but also quality of life and social functioning, it is difficult
to assess the risk–benefit profile of these medications prescribed
over the long term. None of the included trials provided data on
long-term (i.e., $6 mo) outcomes comparing adjunctive antipsy-
chotic medication treatment to adjunctive placebo. Our failure to
find long-term outcome data is consistent with that of previous
research teams [17,62]. For example, one systematic review of
long-term, two-arm parallel randomized controlled antidepressant
trials initially identified 2,693 abstracts, only to ultimately include
six trials [62]. This limitation is shared with other treatments; there
is very little understanding of how adjunctive treatments for
depression influence long-term well-being.
In addition to providing a thorough assessment of efficacy
outcomes, our meta-analysis departs from the literature in a
second notable way by comprehensively summarizing the avail-
able safety information on these medications. Such safety data
have not been included in prior quantitative reviews, but our
conclusions echo concerns raised in previous meta-analyses and a
narrative review regarding potential treatment-related harms
associated with use of atypical antipsychotic medication in the
adjunctive treatment of depression [6–8]. Overall, we found that
treatment was linked to several adverse events, including akathisia
(aripiprazole), sedation (quetiapine, OFC, and aripiprazole),
abnormal metabolic laboratory results (quetiapine and OFC),
and weight gain (all four drugs, especially OFC). Measures of
absolute benefit and harm (NNT and NNH) provide an intuitive
metric for understanding treatment-related benefits and harms.
However, these measures are dependent on baseline control group
risk, which may vary substantially across clinical subgroups [63].
Thus, our findings in terms of NNT and NNH should be
interpreted as estimates of effects for each drug relative to control
participants who may differ from participants treated in clinical
practice.
Our ability to provide an adequate safety profile of these
medications was limited in two respects. First, while 11 of 14
included trials used a structured instrument to elicit adverse events,
these measures were limited to assessing potential EPS- and
akathisia-related events, and, in five studies, sexual functioning. No
study reported using a structured checklist to elicit adverse events
outside of EPS, akathisia, or sexual functioning, which is a
substantial limitation given that adverse events are reported with
as much as 20 times greater frequency when elicited through
structured checklists versus being recorded in response to patient
Figure 3. Response rates by drug and overall.
doi:10.1371/journal.pmed.1001403.g003
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Atypical Antipsychotic Augmentation for MDD
PLOS Medicine | www.plosmedicine.org 15 March 2013 | Volume 10 | Issue 3 | e1001403Table 4. Adverse events individually and by category.
Drug
Study First Author (Year)
[Reference] Event
Events/N on
Drug
Events/N on
Placebo OR (95% CI)
a
Aripiprazole Berman (2007) [75] Fatigue 11/182 6/176
Berman (2009) [82] Fatigue 16/176 8/172
Sedation 10/176 1/172
Marcus (2008) [76] Fatigue 19/189 7/190
Somnolence 13/189 7/190
Total Sedation-related 69/547 29/538 2.56 (1.63–
4.03)
Berman (2007) [75] Tremor 6/182 8/176
Other EPS-related events 2/182 1/176
Berman (2009) [82] Dyskinesia 2/176 0/172
Extrapyramidal disorder 2/176 0/172
Muscle spasms 4/176 1/172
Muscle twitching 3/176 3/172
Psychomotor activity 1/176 0/172
Tremor 5/176 6/172
Marcus (2008) [76] Tremor 12/189 5/190
Total EPS-related 37/547 24/538 1.54 (0.86–
2.74)
Berman (2007) [75] Metabolic labs
b ??
Berman (2009) [82] Metabolic labs
c ??
Marcus (2008) [76] Metabolic labs
d ??
Total Metabolic labs ? ?
Berman (2007) [75] Akathisia 42/182 8/176
Restlessness 26/182 6/176
Berman (2009) [82] Akathisia 32/176 6/172
Restlessness 22/176 6/172
Marcus (2008) [76] Akathisia 49/189 8/190
Restlessness 18/189 1/190
Total Akathisia-related 189/547 35/538 7.47 (5.07–
11.0)
Berman (2007) [75] Weight gain $7% 13/182 2/176
Berman (2009) [82] Weight gain $7% 8/176 2/172
Marcus (2008) [76] Weight gain $7% 6/189 0/190
Total Weight gain $7% 27/547 4/538 5.91 (2.14–
16.29)
OFC Corya (2006) [25] Asthenia 29/243 10/119
Somnolence 53/243 8/119
Shelton (2001) [27] Asthenia 5/10 4/10
Somnolence
e 6/10 5/10
Shelton (2005) [26] Asthenia 30/146 25/210
Somnolence 25/146 27/210
Thase (2007) [85] Fatigue 28/200 16/206
Hypersomnia 21/200 5/206
Sedation 19/200 7/206
Somnolence 35/200 11/206
Total Sedation 240/589 109/535 2.87 (1.64–
5.03)
Corya (2006) [25] Dyskinesia any time (AIMS) 1/227 3/113
Dyskinesia at last two visits (AIMS) 0/227 1/113
Dyskinesia at end point (AIMS) 1/227 1/113
Parkinsonism (SAS) 6/226 7/113
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Drug
Study First Author (Year)
[Reference] Event
Events/N on
Drug
Events/N on
Placebo OR (95% CI)
a
Shelton (2001) [27] Parkinsonism (SAS) 0/10 3/9
Shelton (2005) [26] Dyskinesia any time (AIMS) 2/140 0/197
Dyskinesia at last two visits (AIMS) 0/140 0/197
Dyskinesia at end point (AIMS) 0/140 0/197
Parkinsonism (SAS) 7/140 1/199
Tremor 17/146 8/210
Thase (2007) [85] Dyskinesia any time (AIMS) 1/196 3/201
Dyskinesia at last two visits (AIMS) 0/195 0/201
Dyskinesia at end point (AIMS) 0/194 1/199
Parkinsonism (SAS) 5/192 2/195
Tremor 21/200 18/206
Total EPS-related 61/574 48/522 0.88 (0.25–
3.04)
Corya (2006) [25] Cholesterol high 12/213 0/103
Nonfasting glucose high 6/209 0/103
HbA1c high 10/153 1/77
Shelton (2001) [27] Cholesterol high 1/10 0/10
Nonfasting glucose high 0/10 0/10
Shelton (2005) [26] Cholesterol high 3/133 7/193
Nonfasting glucose high 8/131 3/192
Hyperglycemia 3/146 0/200
Thase (2007) [85] Cholesterol high 9/189 3/194
Fasting glucose high 2/28 0/36
Nonfasting glucose high 6/168 1/170
HbA1c high 8/144 0/165
Triglycerides high 10/189 3/196
Total Metabolic labs
f 78/482 18/455 4.46 (2.07–
9.58)
Corya (2006) [25] Agitation 14/243 4/119
Akathisia any time (Barnes) 23/227 5/109
Shelton (2001) [27] Akathisia 2/10 0/10
Akathisia (Barnes) 3/10 2/9
Shelton (2005) [26] Akathisia (Barnes) 14/138 20/196
Thase (2007) [85] Akathisia (Barnes) 18/188 13/188
Total Akathisia 74/571 44/508 1.48 (0.96–
2.30)
Corya (2006) [25] Prolactin high 43/186 7/89
Shelton (2001) [27] Prolactin high 4/9 0/7
Shelton (2005) [26] Prolactin high 34/119 6/178
Thase (2007) [85] Prolactin high 49/159 23/172
Total Prolactin high
g 130/473 36/446 4.30 (2.36–
7.83)
Corya (2006) [25] Peripheral edema 27/243 1/119
Edema 19/243 1/119
Shelton (2001) [27] Peripheral edema 2/10 0/10
Thase (2007) [85] Peripheral edema 24/200 2/206
Edema 11/200 1/206
Total Edema 83/453 5/335 13.19 (5.46–
31.89)
Corya (2006) [25] Weight gain $10% 53/230 2/114
Shelton (2001) [27] Weight gain $10% 3/10 0/10
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Drug
Study First Author (Year)
[Reference] Event
Events/N on
Drug
Events/N on
Placebo OR (95% CI)
a
Shelton (2005) [26] Weight gain .10% 11/146 0/210
Thase (2007) [85] Weight gain $10% 42/198 2/203
Total Weight gain .10% or weight gain $10% 109/584 4/537 16.28 (7.02–
37.76)
Quetiapine Bauer (2009) [81] Fatigue 46/330 5/161
Lethargy 7/330 2/161
Sedation 37/330 7/161
Somnolence 66/330 5/161
El-Khalili (2010) [83] Fatigue 33/297 7/148
Hypersomnia 6/297 0/148
Sedation 58/297 6/148
Somnolence 86/297 6/148
McIntyre (2007) [84] Sedation/somnolence/lethargy 25/29 14/29
Total Sedation-related 364/656 52/338 8.36 (5.83–
11.98)
Bauer (2009) [81] EPS-related None None
El-Khalili (2010) [83] EPS-related 17/297 5/148
McIntyre (2007) [84] EPS-related None None
Total EPS-related 17/297 5/148 1.66 (0.59–
4.67)
Bauer (2009) [81] Fasting glucose high 15/330 4/161
LDL cholesterol high 47/330 18/161
HDL cholesterol low 13/330 7/161
Total cholesterol high 60/330 14/161
Triglycerides high 40/330 5/161
El-Khalili (2010) [83] Fasting glucose high 11/297 5/148
HbA1c high 2/297 1/148
HDL cholesterol low 18/297 7/148
LDL cholesterol high 12/297 5/148
Total cholesterol high 22/297 2/148
Triglycerides high 29/297 6/148
McIntyre (2007) [84] Metabolic labs
h ??
Total Metabolic labs
i 269/627 74/309 2.45 (1.80–
3.34)
Bauer (2009) [81] Shift from ,3t o$3 metabolic risk factors 27/330 16/161
El-Khalili (2010) [83] Shift from ,3t o$3 metabolic risk factors
j 50/297 9/148
Total Shift from ,3t o$3 metabolic risk factors 77/627 25/309 1.57 (0.42–
5.92)
El-Khalili (2010) [83] Akathisia 6/297 1/148
Restlessness 5/297 2/148
Total Akathisia-related 11/297 3/148 1.75 (0.47–
6.55)
Bauer (2009) [81] Elevated prolactin
k 6/330 3/161
Total Elevated prolactin 6/330 3/161 0.96 (0.23–
3.96)
Bauer (2009) [81] Weight gain $7% 14/330 2/161
El-Khalili (2010) [83] Weight gain $7% 13/297 3/148
McIntyre (2007) [84] Weight gain $7% 4/18 0/14
Total Weight gain $7% 31/645 5/323 2.86 (1.11–
7.37)
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systematically was demonstrated historically in the case of selective
serotonin reuptake inhibitors: in registration trials, sexual dys-
function was neither systematically assessed nor found to be
frequently spontaneously reported by patients [64,65]. Further
investigation indicated, however, that sexual side effects on
Table 4. Cont.
Drug
Study First Author (Year)
[Reference] Event
Events/N on
Drug
Events/N on
Placebo OR (95% CI)
a
Risperidone Keitner (2009) [73] Fatigue 0/62 2/33
Tired 0/62 2/33
Mahmoud (2007) [44] Fatigue 5/137 0/131
Lethargy 1/137 3/131
Somnolence 7/137 2/131
Reeves (2008) [77] Somnolence 2/12 1/11
Total Sedation-related 15/211 10/175 0.88 (0.11–
7.55)
Mahmoud (2007) [44] Dystonia 0/137 1/131
Tremor 1/137 1/131
Total EPS-related 1/137 2/131 0.47 (0.04–
5.29)
Keitner (2009) [73] Metabolic labs
l ??
Mahmoud (2007) [44] Metabolic labs
l ??
Reeves (2008) [77] Metabolic labs
l ??
Total Metabolic labs ? ?
Mahmoud (2007) [44] Akathisia 1/137 0/131
Total Akathisia-related 1/137 0/131 2.89 (0.12–
71.58)
Keitner (2009) [73] Edema 0/62 0/33
Mahmoud (2007) [44] Peripheral edema 4/137 1/131
Reeves (2008) [77] Edema 0/12 0/11
Total Edema 4/211 1/175 3.91 (0.43–
35.45)
Keitner (2009) [73] Weight gain $7% 2/62 0/33
Mahmoud (2007) [44] Weight gain $7%
m ??
Reeves (2008) [77] Weight gain $7%
m ??
Total Weight gain $7% 2/62 0/33 2.77 (0.13–
59.38)
aTrials with no events in either study arm are not included in summary OR calculations.
bThe clinical registry report indicated that statistically significant differences emerged between drug and placebo in glucose, total cholesterol, fasting LDL cholesterol,
nonfasting and fasting triglycerides, and prolactin. These differences were not reported quantitatively and were described as not ‘‘clinically meaningful.’’
cMedian levels of change in fasting total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, and fasting plasma glucose were reported. Categorical measures
(i.e., numbers of patients who had abnormal scores) were not reported. The clinical trial registry noted that there was a statistically significant but clinically
nonmeaningful difference between drug and placebo on nonfasting LDL cholesterol.
dData on metabolic parameters were reported in terms of median change, but no categorical reporting of laboratory abnormalities was provided. Differences between
drug and placebo were reported as not statistically significant in terms of median change on glucose, cholesterol, and triglycerides.
eBecause the total number of events in the OFC group was higher than the sample size of the group, an effect size could not be calculated, and it was thus not factored
into the overall effect size estimate for sedation. Given the very small sample of the study, this makes virtually no difference in the overall effect size estimate.
fThe number of participants providing data differed substantially across metabolic testing parameters. The average sample size across the metabolic testing groups
provided the denominator for the pooled number of abnormal metabolic test results in each trial, with the total number of participants who experienced an abnormal
metabolic testing result comprising the numerator. A participant may have experienced more than one event. Also, boundaries of abnormal tests were defined by
standard Lilly reference ranges, a resource not available to our research team.
gBoundaries of abnormal tests were defined by standard Lilly reference ranges, a resource not available to our research team.
hTriglycerides and unclearly described laboratory tests were completed in this study, but the results were described only as yielding ‘‘no clinically significant differences’’
between groups.
iAbnormal metabolic laboratory values were defined as follows: fasting glucose $126 mg/dl, LDL cholesterol $160 mg/dl, HDL cholesterol #40 mg/dl, total cholesterol
$240 mg/dl, and triglycerides $200 mg/dl.
jThe clinical trial registry entry noted that approximately 17% of patients taking quetiapine met this criterion, compared to 6% of placebo patients. We extracted
numbers of patients based on these percentages.
kDefined as .20 ng/ml for males and .30 ng/ml for females.
lThese parameters were apparently not measured.
mWeight gain was provided in terms of means and standard deviations; however, no categorical measure of significant weight gain was reported.
AIMS, Abnormal Involuntary Movement Scale; Barnes, Barnes Akathisia Scale; HbA1c, glycated hemoglobin; SAS, Simpson-Angus Scale.
doi:10.1371/journal.pmed.1001403.t004
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[19]. While the collection of adverse event data via structured
checklists is a more sensitive method of collecting adverse event
data, it may result in many common (mostly minor) health
problems being endorsed even if they are not due to treatment,
potentially leading to decreased specificity in differentiating
medications from placebo [66]. To bridge the differences between
the systematic and open-ended assessment of adverse events in
clinical trials, some sort of hybrid method of collecting adverse
event data could be performed, such as randomly assigning some
participants within both the active treatment and placebo groups
to complete a structured checklist while assigning others to
complete an open-ended assessment of adverse events.
A second constraint on our ability to adequately summarize the
drugs’ safety profiles is that many adverse events were not reported in
journalarticlesandthatsomeofthedatawereincompleteorreported
in a fashion that may have obscured treatment-related harms. We
agree with the Cochrane reviewers that ‘‘data on side effects were
often very poorly described’’ [9]. Conceptually similar events such as
sedation, fatigue, and somnolence were sometimes reported
separately, often with no attempt to pool them together. This is in
direct contradiction to FDA guidance, which states that events that
‘‘represent the same phenomenon (e.g., somnolence, sedation,
drowsiness) should ordinarily be grouped together as a single adverse
reaction to avoid diluting or obscuring the true effect’’ [67].
Given the notable side effect profiles of the studied drugs, it is
likely that the double-blind was significantly compromised;
however, none of the included trials tested the integrity of
blinding. For example, patients who rapidly gained weight in an
OFC trial, who complained of akathisia in an aripiprazole trial, or
who reported sedation in a quetiapine trial would likely cue the
awareness of study personnel that they were assigned to the active
drug condition. Assuming that proper informed consent was
obtained, participants were also likely to accurately guess their
treatment assignment based on side effect cues [68,69]. This could
have led to inflated efficacy ratings by clinical raters and
participants [70,71]. The lack of protocols assessing the integrity
of the double-blind in the trials included in our meta-analysis is
consistent with the wider clinical trials literature [72]. The
potential for unblinding to cause inflated efficacy ratings among
clinical raters could be substantially limited if efficacy outcomes
were assessed by different personnel than those who assessed
adverse events [70]. Yet the use of separate raters to assess efficacy
and safety outcomes was reported in only one trial [73].
The FDA statistical reviewer for aripiprazole [74] wrote
regarding Berman et al. [75] that ‘‘the medical reviewer is
concerned about the considerable number of protocol violations
in the study primarily due to usage of opiates/barbiturates’’ [74].
Regarding the Marcus et al. [76] trial, the FDA reviewer wrote that
the difference between groups in the number of participants who
used prohibited medications was ‘‘huge’’ [74], with nine patients in
the placebo group doing so compared to 24 in the aripiprazole
group. The reviewer thus performed a separate analysis, excluding
patients in the two trials who violated the study protocol, the results
of which indicated a minimal, non-statistically significant effect of
aripiprazole on functional status. In the journal articles, this
potentially important issue is not mentioned. The FDA reviewer
reported results only from reanalysis of the MADRS and SDS, so it
is unknown to what extent these protocol violations may have
impacted results on other outcome measures [74].
Our results differ somewhat from those of Nelson and
Papakostas, whose meta-analysis concluded that augmentation with
atypical antipsychotics was effective and, further, that ‘‘this body of
evidence is considerably larger than that for any other augmenta-
tion strategy in the treatment of major depressive disorder’’ [6].
Therearesevendifferencesinouranalysesthat providereasonswhy
we reached different conclusions. The greatest divergence in our
results was regarding OFC, for which we found a lower OR
favoring OFC for remission (1.42) than did Nelson and Papakostas
(1.83).Inthis firstinstance,Nelsonand Papakostas utilized whatever
definition of remission was provided by the authors of each study,
whereas we used a more restrictive definition. Three OFC trials
defined remission as achieving a MADRS score of #8 at two
consecutivevisits—evenif patientsrelapsed duringthetrial[25–27].
Figure 4. Funnel plot of trim and fill analysis. Open circles represent published studies; filled circles represent imputed unpublished studies.
The overall effect size changes from 0.34 to 0.32 when including these imputed trials.
doi:10.1371/journal.pmed.1001403.g004
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participants were more likely to relapse than placebo-treated
participants; this contributed to our finding a less favorable result
for OFC in terms of remission. Second, we extracted data from all
comparison groups that received adjunctive placebo treatment,
whereas Nelson and Papakostas excluded one comparison group
from each of two OFC trials [25,26]. Third, Nelson and Papakostas
estimated a significant treatment effect for OFC on response,
whereas we did not. This difference seems due to a combination of
our inclusion of all adjunctive placebo comparison groups and our
use of random effects analysis as opposed to their use of a fixed
effects model [38]. Our fourth point of difference was that Nelson
and Papakostasincluded data from two conference presentations on
quetiapine that showed positive findings; we were unable to obtain
data from these authors despite three emailed requests over a span
of 4 wk. Additionally, we attempted to contact one author via
phone; the attempt did not result in the release of any data.
Nonetheless, the pooled ORs generated in our analyses for
quetiapine in terms of response (1.53) and remission (1.79) were
quite similar to those published in Nelson and Papakostas’s meta-
analysis (1.60 and 1.89, respectively). Our fifth difference was the
use of different definitions of remission in one risperidone trial [73],
and the sixth difference was Nelson and Papakostas’s inclusion of
data from one small risperidone trial from which we were unable to
extract remission data [77], leading to our finding a slightly lower
rate of remission (OR of 2.37 versus 2.63). Lastly, and most
importantly, the primary point of difference is that our analysis
provides a more comprehensive appraisal of treatment efficacy and
safety, which, as discussed above, presents a more accurate
assessment of the comparative risks and benefits of treatment.
Our review adds to the Cochrane review on this topic [9] by
filling in three important data gaps: (1) unpublished data from the
FDA and clinical trial registry reports, (2) data on functioning and
quality of life outcomes, and (3) data on metabolic laboratory
parameters. Thus, our dataset contained more outcomes and often
provided a more comprehensive assessment of included outcomes
than the Cochrane review. For instance, the Cochrane review
included data from one trial that reported data on clinically
significant weight gain for patients on OFC, whereas we included
dataon both mean weight changes and binary measures of clinically
significant weight gain from four such trials. We includedlaboratory
dataforseveralmetabolicparametersforboth quetiapineandOFC.
Despite some differences in methodology, we agree with the
Cochrane review that the evidence supporting the use of adjunctive
atypical antipsychotics for depression is modest.
Several methodological issues also bear mention. First, while all
trials were described as randomized, double-blind trials, only three
trials clearly described adequate sequence generation procedures;
in the remaining studies, such procedures were unclear. A lack of
appropriate randomization or differences in the taste, smell, or
appearance of the medication and placebo may allow study
personnel and/or participants to guess their treatment assignment.
As purportedly double-blind trials with unclear or inadequate
randomization are associated with larger effects than trials in
which adequate randomization is clearly described, this leads to
the possibility that the current set of efficacy ratings were inflated
to an unknown extent [21,78]. Second, the design of some of the
included trials may have compromised their validity. In each of the
aripiprazole trials, patients were treated with an antidepressant
plus adjunctive placebo for 8 wk; at that point, those who showed
a treatment response were eliminated from the study, and the
remaining patients were assigned to either remain on the same
treatment or receive adjunctive aripiprazole in place of adjunctive
placebo. Thus, all patients taking placebo during the randomized
trial had clearly demonstrated poor response to placebo treatment
and were likely predisposed to perform poorly during the
randomized portion of the trial, thereby possibly inflating the
estimated efficacy of the study drug [79].
In any systematic review, publication bias is a potentially serious
problem [10,80]. To incorporate as much data as possible, we
conducted a thorough literature search and included unpublished
data. We did not uncover the existence of any additional
unpublished negative trials in our search, but this does not mean
that such trials do not exist. Given the small number of trials for
each drug in our study, we lacked statistical power to conduct a
formal analysis of publication bias for each drug. However, when
pooling across drugs, we detected that publication bias may have
slightly enhanced the overall effect size on depression measures.
Our results likely represent an upper boundary for the efficacy of
these compounds (as demonstrated in prior meta-analyses),
assuming that relevant unpublished data are more negative than
positive in terms of efficacy [10,11].
We are aware of no trials that have directly compared
adjunctive atypical antipsychotic medication treatment to other
adjunctive treatments such as psychotherapy or lithium, or to
other treatment strategies such as switching the antidepressant
medication initially used for treatment. Further study may answer
critical outstanding questions regarding the safety profiles and
longer-term outcomes associated with these medications. Taken
together, our meta-analysis found evidence of (1) some improve-
ment in clinician-assessed depressive symptoms, (2) little evidence
of substantial benefit in overall well-being, and (3) abundant
evidence of potential treatment-related harm. Our comprehensive
evaluation of safety and both relative and absolute efficacy
provides critical insight that may be useful for clinicians attempting
to thoroughly understand the risk–benefit profiles of these
adjunctive treatments for major depressive disorder.
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Background Everyone feels miserable occasionally. But for
people who are clinically depressed, feelings of sadness and
hopelessness and physical symptoms such as sleeping badly
can last for months or years and can make them feel life is no
longer worth living. Depression affects one in six people at
some time during their life. Clinicians diagnose depression
by asking their patients a series of questions about their
feelings and symptoms. The answer to each question is
given a score, and the total score from the questionnaire
(‘‘depression rating scale’’) indicates the severity of depres-
sion. Treatment of depression often involves talking treat-
ments (psychotherapy) such as cognitive behavioral therapy,
which helps people change negative ways of thinking and
behaving and antidepressant drugs, most commonly ‘‘selec-
tive serotonin reuptake inhibitors’’ such as fluoxetine and
paroxetine.
Why Was This Study Done? Atypical antipsychotic
medications (for example, aripiprazole, olanzapine/fluoxetine
combination [OFC], quetiapine, and risperidone) are also
widely prescribed for the treatment of depression. These
drugs, which were developed to treat mental illnesses that
are characterized by a loss of contact with reality, are used as
adjunctive therapy for depression. That is, they are used in
addition to antidepressant drugs. Clinicians wrote nearly four
million prescriptions for adjunctive treatment of depression
with atypical antipsychotic medications in 2007–2008 in the
US alone. However, it is not known whether the benefits of
using these drugs to treat depression outweigh their side
effects, which include weight gain, sedation, and akathisia (a
feeling of inner restlessness resulting in an urge to move,
which may or may not be accompanied by increased
movement). Here, the researchers undertake a systematic
review and meta-analysis of the efficacy and safety profiles of
atypical antipsychotic medications used for the adjunctive
treatment of depression. A systematic review uses prede-
fined criteria to identify all the research on a given topic; a
meta-analysis is a statistical approach that combines the
results of several studies.
What Did the Researchers Do and Find? The researchers
identified 14 short-term randomized controlled trials (dura-
tion 4–12 weeks) that compared adjunctive antipsychotic
medications (aripiprazole, OFC, quetiapine, or risperidone) to
placebo (dummy drug) in the treatment of depression that
had not responded to antidepressant medication alone. All
four drugs had statistically significant effects (effects unlikely
to have happened by chance) on remission, which was most
commonly defined as a score of less than eight at the study
end point on the Montgomery–Asberg Depression Rating
Scale. The researchers calculated the number of patients that
would have to be treated for one patient to achieve
remission (number needed to treat, or NNT). For OFC, the
NNT was 19; for all the other drugs it was nine. All the drugs
except OFC also significantly improved response rates
(defined as a 50% improvement in depression rating score).
However, the medications provided little or no benefit in
terms of functioning and quality of life, except for risperi-
done, which had a small-to-moderate effect on quality of life.
Finally, treatment with atypical antipsychotic medications
was linked to several adverse effects, including weight gain
(all four drugs) and akathisia (aripiprazole).
What Do These Findings Mean? These results suggest
that atypical antipsychotic medications for the adjunctive
treatment of depression are efficacious in reducing observer-
rated depressive symptoms. However, clinicians should
interpret this conclusion cautiously for several reasons. First,
adjunctive treatment with atypical antipsychotics provided
only small-to-moderate benefits. Moreover, shortcomings in
study design and data reporting methods may have inflated
the apparent benefits of treatment and reduced the
apparent incidence of adverse events. Second, this study
provides little evidence that adjunctive treatment with
atypical antipsychotics improves patients’ quality of life or
reduces their functional impairment. Finally, this study
highlights abundant evidence of potential treatment-related
harm. This evaluation of the safety and efficacy of adjunctive
treatments for clinical depression provides critical insights
that should help clinicians better understand the risk–benefit
profiles of this approach to the treatment of major
depressive disorder.
Additional Information Please access these websites via
the online version of this summary at http://dx.doi.org/10.
1371/journal.pmed.1001403.
N The US National Institute of Mental Health provides
information on all aspects of depression (in English and
Spanish); it has a webpage on mental health medications
that includes information about atypical antipsychotics
N The UK National Health Service Choices website also
provides detailed information about depression and
includes personal stories about depression
N More personal stories about depression are available from
healthtalkonline.org
N The UK charity Mind provides information on depression
and on antipsychotic drugs; Mind also includes personal
stories about depression on its website
N MedlinePlus provides links to other resources about
depression (in English and Spanish)
N Healthy Skepticism is an international nonprofit member-
ship association that aims to improve health by reducing
harm from misleading health information
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